NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SRDX

Surmodics, Inc

Jul 11 • 04:00PM ET

30.87

Dollar change -0.15
Percentage change -0.48	%

Healthcare • Medical Devices • USA • NASD

Peers: ALGN TFX DXCM PODD BRKR RGEN IART LMAT PEN MNKD

| Held by: VTI IWM VXF IWO IHI SCHA VTWO VHT DFAS IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	3.97%	Shs Outstand	14.30M	Perf Week	2.93%
Market Cap	441.42M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.00%	Shs Float	13.73M	Perf Month	5.72%
Enterprise Value	443.08M	PEG	-	EPS next Q	-0.18	Inst Own	83.76%	Short Float	2.49%	Perf Quarter	9.27%
Income	-19.86M	P/S	3.63	EPS this Y	-70.31%	Inst Trans	-7.46%	Short Ratio	4.45	Perf Half Y	-20.81%
Sales	121.58M	P/B	4.00	EPS next Y	53.21%	ROA	-11.48%	Short Interest	0.34M	Perf YTD	-22.05%
Book/sh	7.71	P/C	14.17	EPS next 5Y	-	ROE	-16.96%	52W High	42.25 -26.93%	Perf Year	-26.92%
Cash/sh	2.18	P/FCF	-	EPS past 3/5Y	- -	ROIC	-13.99%	52W Low	26.00 18.73%	Perf 3Y	-17.90%
Dividend Est.	-	EV/EBITDA	96.95	Sales past 3/5Y	6.24% 4.73%	Gross Margin	70.51%	Volatility	3.30% 2.88%	Perf 5Y	-27.60%
Dividend TTM	-	EV/Sales	3.64	EPS Y/Y TTM	-245.49%	Oper. Margin	-3.22%	ATR (14)	0.93	Perf 10Y	30.47%
Dividend Ex-Date	-	Quick Ratio	3.99	Sales Y/Y TTM	-14.96%	Profit Margin	-16.34%	RSI (14)	63.37	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.14	EPS Q/Q	-2196.55%	SMA20	4.56%	Beta	1.30	Target Price	43.00
Payout	-	Debt/Eq	0.30	Sales Q/Q	-12.12%	SMA50	6.66%	Rel Volume	0.98	Prev Close	31.02
Employees	389	LT Debt/Eq	0.29	Earnings	Apr 30 BMO	SMA200	-8.79%	Avg Volume	76.92K	Price	30.87
IPO	Mar 04, 1998	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.74% -12.86%	Trades		Volume	75,417	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Upgrade	Lake Street	Hold → Buy	$43
Jun-13-23	Upgrade	Needham	Hold → Buy	$36
Feb-13-23	Downgrade	Needham	Buy → Hold
Jul-23-20	Upgrade	Needham	Hold → Buy
Dec-11-19	Downgrade	Needham	Buy → Hold
Nov-01-19	Downgrade	Lake Street	Buy → Hold	$75 → $50
Aug-01-19	Reiterated	Needham	Buy	$65 → $68
May-02-19	Reiterated	Needham	Buy	$74 → $65
May-02-19	Reiterated	Lake Street	Buy	$90 → $75
Feb-21-19	Reiterated	Needham	Buy	$69 → $74
May-16-18	Reiterated	Needham	Buy	$46 → $55
Mar-01-18	Upgrade	Sidoti	Neutral → Buy
Feb-28-18	Reiterated	Lake Street	Buy	$35 → $38
Feb-28-18	Initiated	Needham	Buy	$42
Jul-14-17	Initiated	Lake Street	Buy	$40
Nov-21-16	Downgrade	Barrington Research	Outperform → Mkt Perform
Oct-06-16	Downgrade	Sidoti	Buy → Neutral
May-03-16	Reiterated	Barrington Research	Outperform	$27 → $30
Aug-06-15	Reiterated	Barrington Research	Outperform	$28 → $29
Mar-27-15	Initiated	Dougherty & Company	Buy	$33

Show Previous Ratings

Jul-03-25 07:18AM	Surmodics still recovering after June cyberattack (Medical Device Network)
Jun-06-25 11:31AM	QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound? (Zacks)
May-30-25 11:31AM	Why Is SurModics (SRDX) Up 6% Since Last Earnings Report? (Zacks)
May-02-25 08:30AM	Are Options Traders Betting on a Big Move in Surmodics Stock? (Zacks)
May-01-25 12:46PM	SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts (Zacks)
10:00AM	Loading…
Apr-30-25 10:00AM	SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.44%
08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:14AM	SurModics: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance (Business Wire)
Apr-28-25 06:00PM	Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 (Business Wire) +5.57%
Apr-22-25 07:00AM	Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil Drug-Coated Balloon (Business Wire)
Apr-18-25 07:00AM	Illinois, Minnesota join FTC challenge against $627M Surmodics buyout (MedTech Dive)
Apr-04-25 12:36PM	SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System (Zacks)
Apr-03-25 12:41PM	Surmodics launches Pounce XL thrombectomy system (Medical Device Network)
07:00AM	Surmodics Announces Commercial Release of Pounce XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries (Business Wire)
09:30AM	Loading…
Mar-10-25 09:30AM	FTC sues to block GTCRs unlawful acquisition of Surmodics (Medical Device Network)
Mar-07-25 05:00AM	FTC challenges $627M private equity takeover of Surmodics (MedTech Dive)
Mar-06-25 09:00PM	Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR (Business Wire)
04:22PM	US FTC sues to block private equity purchase of medical company (Reuters)
Feb-03-25 09:35AM	SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:00AM	Surmodics Announces Successful Early Clinical Use of Pounce XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries (Business Wire)
Jan-30-25 09:30AM	Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics (Zacks)
08:20AM	SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:24AM	SurModics: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results (Business Wire)
Jan-14-25 09:35AM	After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX) (Zacks)
Jan-03-25 12:00PM	SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Dec-06-24 11:31AM	Why Is SurModics (SRDX) Up 4% Since Last Earnings Report? (Zacks)
Nov-22-24 01:01AM	SurModics Inc. Faces Legal Hurdles: Shareholder Lawsuits Threaten Merger and Financial Stability (TipRanks)
Nov-12-24 12:45PM	SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
08:20AM	Loading…
Nov-06-24 08:20AM	SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:28AM	SurModics: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results (Business Wire)
Oct-30-24 02:30PM	Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce Thrombectomy System (Business Wire)
Oct-01-24 07:00AM	Surmodics Receives FDA 510(k) Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter (Business Wire)
Sep-06-24 09:55AM	SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-05-24 09:35AM	Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround (Zacks)
Aug-15-24 09:35AM	SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jul-31-24 10:30AM	Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings (Zacks)
08:20AM	SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:16AM	SurModics: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results (Business Wire)
Jun-11-24 10:38AM	Surmodics (SRDX) Inks Group Purchasing Agreement With Premier (Zacks)
Jun-10-24 07:00AM	Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. (Business Wire)
May-31-24 11:31AM	Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report? (Zacks)
11:28AM	Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M (Zacks)
04:45AM	Surmodics agrees to $627M private equity buyout (MedTech Dive)
May-29-24 04:07PM	Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals (Investor's Business Daily) +19.94%
07:00AM	Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million (Business Wire)
May-20-24 10:49AM	Here's Why You Should Hold Surmodics (SRDX) Stock for Now (Zacks)
May-03-24 01:12PM	Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up (Zacks) -5.96%
May-02-24 12:38PM	Surmodics, Inc. (NASDAQ:SRDX) Q2 2024 Earnings Call Transcript (Insider Monkey)
03:01AM	Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-01-24 02:05PM	Top Midday Gainers (MT Newswires) +29.74%
11:54AM	SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
09:30AM	SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:30AM	SurModics (SRDX) Q2 Earnings and Revenues Top Estimates (Zacks)
07:32AM	SurModics: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance (Business Wire)
Apr-19-24 07:00AM	Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 (Business Wire)
Apr-17-24 10:01AM	Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know (Zacks)
Mar-20-24 11:29AM	Here's Why You Should Hold Surmodics (SRDX) Stock for Now (Zacks)
Feb-27-24 08:00AM	Surmodics to Participate in Upcoming Investor Conferences in March and April (Business Wire)
Feb-02-24 10:11AM	Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View (Zacks)
09:58AM	Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-01-24 01:03PM	Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024 (GuruFocus.com) -7.90%
09:30AM	SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:10AM	SurModics (SRDX) Reports Break-Even Earnings for Q1 (Zacks)
07:11AM	SurModics: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance (Business Wire)
Jan-23-24 10:15AM	Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform (Zacks)
Jan-22-24 07:30AM	Surmodics Announces Successful Early Clinical Use of Pounce LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee (Business Wire)
Jan-16-24 07:30AM	Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1 (Business Wire)
07:30AM	Surmodics to Host Virtual Annual Meeting of Shareholders (Business Wire)
Dec-14-23 07:14AM	SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock? (Zacks)
Dec-12-23 11:31AM	Here's Why You Should Retain Surmodics (SRDX) Stock for Now (Zacks)
Nov-16-23 07:30AM	Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium (Business Wire)
07:30AM	Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium (Business Wire)
Nov-14-23 04:05PM	Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28 (Business Wire) +7.05%
Nov-11-23 02:10PM	Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 12:44PM	Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y (Zacks) -5.93%
12:33AM	Q4 2023 Surmodics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 03:10PM	Surmodics Inc (SRDX) Reports Fiscal Year 2023 Earnings Growth and Introduces FY 2024 Guidance (GuruFocus.com) +7.36%
09:30AM	SurModics (SRDX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:00AM	SurModics: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance (Business Wire)
Nov-07-23 07:30AM	Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium (Business Wire)
07:30AM	Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15 (Business Wire)
Oct-31-23 07:30AM	Surmodics Announces Launch of Preside Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications (Business Wire)
Oct-10-23 11:28AM	3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio (Zacks)
07:30AM	Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8 (Business Wire)
Sep-12-23 10:42AM	Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock? (Zacks) -7.11%
Sep-06-23 11:04AM	Why You Should Add Surmodics (SRDX) Stock to Your Portfolio (Zacks)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-09-23 05:05PM	Surmodics to Participate in Upcoming Investor Conferences in August (Business Wire)
Aug-03-23 01:03PM	Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up (Zacks)
06:47AM	Surmodics (NASDAQ:SRDX) Might Be Having Difficulty Using Its Capital Effectively (Simply Wall St.)
Aug-02-23 09:30AM	SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:55AM	SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:47AM	SurModics: Fiscal Q3 Earnings Snapshot (AP Finance)

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heine Lisa Wipperman	Director	Feb 18 '25	Option Exercise	27.30	2,640	72,072	16,093	Feb 20 04:12 PM
DANTZKER DAVID	Director	Feb 13 '25	Option Exercise	27.30	5,275	144,008	44,399	Feb 18 05:22 PM
BEDOYA JOSE H	Director	Feb 14 '25	Option Exercise	27.30	5,275	144,008	34,232	Feb 18 05:20 PM
KNIGHT SUSAN E	Director	Jan 24 '25	Option Exercise	27.30	7,358	200,873	42,506	Jan 28 05:39 PM
Arens Timothy J.	Chief Financial Officer	Nov 26 '24	Sale	39.44	7,009	276,453	70,350	Nov 27 04:30 PM
TIMOTHY ARENS	Officer	Nov 26 '24	Proposed Sale	39.44	7,009	276,453		Nov 26 04:53 PM
Stich Joseph J.	SVP of HR, President IVD	Aug 21 '24	Option Exercise	33.20	21,285	706,662	83,405	Aug 23 04:06 PM
Maharaj Gary R	President & CEO	Aug 21 '24	Option Exercise	33.20	61,017	2,025,764	253,151	Aug 23 04:05 PM
OLSON CHARLES W	SVP, Medical Device Coatings	Aug 16 '24	Option Exercise	33.20	18,447	612,440	70,698	Aug 20 04:25 PM
Arens Timothy J.	Chief Financial Officer	Aug 16 '24	Option Exercise	33.20	18,447	612,440	94,088	Aug 20 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRDX

Surmodics, Inc

Upgrade your FINVIZ experience